![Diagnostics | Free Full-Text | Framing Cause-Effect Relationship of Acute Coronary Syndrome in Patients with Chronic Kidney Disease Diagnostics | Free Full-Text | Framing Cause-Effect Relationship of Acute Coronary Syndrome in Patients with Chronic Kidney Disease](https://pub.mdpi-res.com/diagnostics/diagnostics-11-01518/article_deploy/html/images/diagnostics-11-01518-g001.png?1629972107)
Diagnostics | Free Full-Text | Framing Cause-Effect Relationship of Acute Coronary Syndrome in Patients with Chronic Kidney Disease
![Optimizing the Technique for Invasive Fractional Flow Reserve to Assess Lesion-Specific Ischemia | Circulation: Cardiovascular Interventions Optimizing the Technique for Invasive Fractional Flow Reserve to Assess Lesion-Specific Ischemia | Circulation: Cardiovascular Interventions](https://www.ahajournals.org/cms/asset/dbf9626a-39ab-4ddc-a598-884f6d771405/e007939fig06.jpg)
Optimizing the Technique for Invasive Fractional Flow Reserve to Assess Lesion-Specific Ischemia | Circulation: Cardiovascular Interventions
![Frontiers | A Resampling Method to Improve the Prognostic Model of End-Stage Kidney Disease: A Better Strategy for Imbalanced Data Frontiers | A Resampling Method to Improve the Prognostic Model of End-Stage Kidney Disease: A Better Strategy for Imbalanced Data](https://www.frontiersin.org/files/MyHome%20Article%20Library/730748/730748_Thumb_400.jpg)
Frontiers | A Resampling Method to Improve the Prognostic Model of End-Stage Kidney Disease: A Better Strategy for Imbalanced Data
![Changes in white matter functional networks during wakefulness and sleep - Yang - 2022 - Human Brain Mapping - Wiley Online Library Changes in white matter functional networks during wakefulness and sleep - Yang - 2022 - Human Brain Mapping - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/0cd4743a-358a-4e30-8829-5091a69454e8/hbm25961-fig-0001-m.jpg)
Changes in white matter functional networks during wakefulness and sleep - Yang - 2022 - Human Brain Mapping - Wiley Online Library
![Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies - The Lancet Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies - The Lancet](https://www.thelancet.com/cms/asset/8312cce9-0649-4da1-9ea6-fa80f2120e48/gr1.jpg)
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies - The Lancet
![5-Chlorothiophene-2-carboxylic Acid [(S)-2-[2-Methyl-3-(2-oxopyrrolidin-1-yl)benzenesulfonylamino]-3-(4-methylpiperazin-1-yl)-3-oxopropyl]amide (SAR107375), a Selective and Potent Orally Active Dual Thrombin and Factor Xa Inhibitor 5-Chlorothiophene-2-carboxylic Acid [(S)-2-[2-Methyl-3-(2-oxopyrrolidin-1-yl)benzenesulfonylamino]-3-(4-methylpiperazin-1-yl)-3-oxopropyl]amide (SAR107375), a Selective and Potent Orally Active Dual Thrombin and Factor Xa Inhibitor](https://pubs.acs.org/cms/10.1021/jm4005835/asset/images/medium/jm-2013-005835_0020.gif)